dipyridamole has been researched along with Arthritis, Psoriatic in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Arthritis, Psoriatic: A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR." | 7.77 | Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011) |
| "To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR." | 3.77 | Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atzeni, F | 1 |
| Sarzi-Puttini, P | 1 |
| Sitia, S | 1 |
| Tomasoni, L | 1 |
| Gianturco, L | 1 |
| Battellino, M | 1 |
| Boccassini, L | 1 |
| De Gennaro Colonna, V | 1 |
| Marchesoni, A | 1 |
| Turiel, M | 1 |
1 other study available for dipyridamole and Arthritis, Psoriatic
| Article | Year |
|---|---|
Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis.
Topics: Adult; Aged; Arginine; Arthritis, Psoriatic; Atherosclerosis; Biomarkers; Carotid Artery, Common; Co | 2011 |